Beyond beta blockers

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Blocking β-adrenergic receptors is a standard treatment for heart failure, but it limits the normal ability to modulate cardiac function. Targeting therapy further downstream by blocking activation of calcium-calmodulin-dependent protein kinase could provide an alternative.

Original languageEnglish (US)
Pages (from-to)379-380
Number of pages2
JournalNature Medicine
Volume11
Issue number4
DOIs
StatePublished - Apr 2005
Externally publishedYes

Fingerprint

Calcium-Calmodulin-Dependent Protein Kinases
Treatment Failure
Adrenergic Receptors
Heart Failure
Chemical activation
Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Beyond beta blockers. / Bers, Donald M.

In: Nature Medicine, Vol. 11, No. 4, 04.2005, p. 379-380.

Research output: Contribution to journalArticle

Bers, Donald M. / Beyond beta blockers. In: Nature Medicine. 2005 ; Vol. 11, No. 4. pp. 379-380.
@article{1de07f06a4324799b7afb84193839f08,
title = "Beyond beta blockers",
abstract = "Blocking β-adrenergic receptors is a standard treatment for heart failure, but it limits the normal ability to modulate cardiac function. Targeting therapy further downstream by blocking activation of calcium-calmodulin-dependent protein kinase could provide an alternative.",
author = "Bers, {Donald M}",
year = "2005",
month = "4",
doi = "10.1038/nm0405-379",
language = "English (US)",
volume = "11",
pages = "379--380",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Beyond beta blockers

AU - Bers, Donald M

PY - 2005/4

Y1 - 2005/4

N2 - Blocking β-adrenergic receptors is a standard treatment for heart failure, but it limits the normal ability to modulate cardiac function. Targeting therapy further downstream by blocking activation of calcium-calmodulin-dependent protein kinase could provide an alternative.

AB - Blocking β-adrenergic receptors is a standard treatment for heart failure, but it limits the normal ability to modulate cardiac function. Targeting therapy further downstream by blocking activation of calcium-calmodulin-dependent protein kinase could provide an alternative.

UR - http://www.scopus.com/inward/record.url?scp=17644383288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17644383288&partnerID=8YFLogxK

U2 - 10.1038/nm0405-379

DO - 10.1038/nm0405-379

M3 - Article

C2 - 15812516

AN - SCOPUS:17644383288

VL - 11

SP - 379

EP - 380

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 4

ER -